Sanofi inked a deal with the antibody discovery experts at Adimab, partnering up to generate a fleet of potential medicines.
With recent news of clinical trials for its low-cost HPV vaccine, the Serum Institute has already made waves in the world of Big Pharma. The India-based vaccinemaker is now gearing up to challenge the world's leading vaccinemakers in another area: pertussis.
3M pronounced last week that its Hollow Microstructure Transdermal System for home drug delivery by patients is available for licensing at the Drug Delivery Partnerships conference in Boca Raton, FL.
Astellas Pharma is getting a piece of the vaccine pie. The Japanese company is joining forces with U.S.-based Immunomic Therapeutics to develop the latter's vaccine to treat allergies caused by Japanese red cedar.
Ortho-Clinical Diagnostics has signed an exclusive deal worth up to $69 million with commercial-stage company Quotient to distribute and sell a blood transfusion diagnostics platform in development.
T2 Biosystems inked an $8.5 million deal with Canon U.S. Life Sciences to develop a rapid diagnostic test for Lyme disease, expanding its offerings and looking to carve a niche in a growing market.
After suffering from unflattering comparisons to Pfizer's infamous inhaled insulin flop Exubera at a cost of $2.8 billion, two FDA rejections, and mockery over its long-running promise to find a marketing partner, Mannkind today announced that its fast-acting Afrezza inhaled insulin is available at U.S. pharmacies.
Medtronic has partnered to provide patient monitoring to home health, hospice and comprehensive post-acute healthcare services LHC Group. The deal was done through its Cardiocom business, which already serves four out of the 5 largest U.S. home healthcare organizations.
Generics giant Mylan is shouldering its way into the blockbuster market for COPD treatments, signing a $265 million deal with the respiratory experts at Theravance Biopharma to get its hands on a late-stage contender.
Welsh CRO Simbec-Orion has agreed to run two late-stage trials, deals the company says affirm the strategy behind its 2014 merger.